CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

心脏生物科技解决方案激活MyCardia AT中国生产流程并进入NMPA最终申报阶段

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.

CBSC secures Health Canada license for CardioHolter AT with $375K order from Your Heart Protector Corp, expanding cardiac monitoring in Canada.

心脏生物科技解决方案获得加拿大卫生部MyCardia AT设备许可证

CBSC secures Health Canada license for CardioHolter AT, lands $375K order with Your Heart Protector Corp, expanding into Canadian market.

正式发布新一代MyCardia AT心脏监测仪

CB Scientific, Inc. (CBSC) has officially launched its next-generation MyCardia AT cardiac event monitor in collaboration with Datrix, LLC. Designed for enhanced remote cardiac monitoring, the FDA-cleared device offers a lightweight, easy-to-use design with seamless integration into the MyCardia app ecosystem. The MyCardia AT monitor enables early detection of cardiac arrhythmias, helping physicians diagnose transient heart conditions more effectively. The device is set to roll out across SE Asia, Hong Kong, Macau, and pending regulatory approvals, Canada and China.

my-Cardia心电图产品与服务在泰国正式上线

Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. to begin exclusive distribution of CB Scientific’s FDA & CE-cleared EKG products to an expansive private and government hospital network.

完成资产购买协议并启动心电图监测业务

An experienced executive management team is leading the way in the FDA and CE-cleared cardiac monitoring products and services arena, using smart phones and cloud-based software technology.

How can we help you?

Tell us what you are interested in.

订阅我们的新闻邮件!

订阅我们的电子报,我们将直接向您发送最新消息。